Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

2418.00

Share Price

2465.00

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 38.56%
Worldwide Healthcare (Ordinary Share) NAV 35.06%
FTSE World 44.11%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 2435.0 0.7% 2418.00 2411.00
14 Feb
107% 0.92%

Discrete performance % over

Fund / BenchmarkMar '15
Feb '16
Mar '16
Feb '17
Mar '17
Feb '18
Worldwide Healthcare (Ordinary Share) Price-9.9545.905.46
Worldwide Healthcare (Ordinary Share) NAV-6.5038.314.45
FTSE World-6.9745.976.12

Discrete performance over

Discrete Performance

Top 10 Holdings

Novo-Nordisk 4.00%
Regeneron Pharmaceuticals, Inc. 3.60%
Wright Medical Group, Inc. 3.50%
Eli Lilly & Co. 3.30%
Alexion Pharmaceuticals, Inc. 3.20%
Boston Scientific, Inc. 3.00%
Intuitive Surgical, Inc. 3.00%
Celgene Corporation 2.90%
CIGNA Corp 2.70%
Chugai Pharmaceutical Co., Ltd. 2.70%

Sectors weighting

Pharmaceuticals 99.90%
Net Current Assets 0.10%

Regional weighting

North America Region 68.00%
Europe Developed ex-UK 16.00%
Japan 8.00%
Asia exc Japan 6.00%
Other Countries 1.00%
Cash/Cash Equivalent 1.00%
UK 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 2465.00
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 50
  • Market Capital (£M) 1210.10
  • Gross Assets (£M) 1283.22
  • Net Assets (£M) 1201.51
  • TER (%) 0.90
  • Historic Dividend Yield (%) 0.92
  • Last AGM 21 Sep 2017
  • Next AGM 21 Sep 2018
  • Last Annual Report Date 14 Jul 2017
  • Next due Report Date 30 Sep 2017
  • Next due Report Type I/R
  • Objective:

    To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.

  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, 0.15% in excess of 500 million and up to 1 billion, 0.125% in excess of 1 billion to 1.5 billion, and over 1.5 billion 0.075%, plus a fixed amount equal to £ 57,500 p.a. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.